Anzeige
Mehr »
Login
Montag, 19.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
InnoCan Pharma: CEO leakt Ergebnisse auf Twitter!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 ISIN: US04962H5063 Ticker-Symbol: YAG2 
Tradegate
19.04.21
20:37 Uhr
1,290 Euro
-0,066
-4,87 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2581,28423:00
1,2201,26822:00

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAtossa Therapeutics Finds Its Share Price Drifting Between Catalysts22
08.04.Atossa Therapeutics says ovarian cancer patient begins treatment with oral endoxifen26
08.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access Pathway14
ATOSSA THERAPEUTICS Aktie jetzt für 0€ handeln
31.03.ATOSSA THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans19
31.03.Atossa Therapeutics EPS misses by $0.7619
31.03.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update8
31.03.ATOSSA THERAPEUTICS, INC. - 10-K, Annual Report5
31.03.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report3
22.03.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market70
22.03.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report25
12.03.Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19346ADELAIDE, AU, Mar 12, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics...
► Artikel lesen
11.03.Atossa gets FDA safe to proceed letter for endoxifen in an ovarian cancer patient31
11.03.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen ...13
01.03.Atossa Therapeutics Has a Covid-19 Connection and Much More106
25.02.Atossa Therapeutics' COVID-19 Nasal Spray Safe In Early-Stage Study31
25.02.Atossa climbs after announcing early-stage data for COVID-19 nasal spray17
10.02.Atossa Therapeutics, Inc.: Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments ...101
06.02.Assessing Atossa Therapeutics88
04.02.Why Atossa Therapeutics Stock Soared Today114
04.02.ATOS Stock: 8 Things for Investors to Know About Atossa Therapeutics as It Soars Thursday54
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,4,30